C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Result of General Meeting

15 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that at the Company's General Meeting held earlier today all resolutions were duly passed. 

Accordingly, pursuant to the passing of Resolution 1, cancellation of admission of the Company's ordinary shares to trading on AIM will become effective at 7.00 a.m. on 26 April 2024. 

In accordance with the passing of Resolution 2, the Company will re-register as a private limited company with the name C4X Discovery Holdings Limited and adopt new articles of association, which is expected to take place in the week commencing 29 April 2024.

The results of the proxy votes received ahead of the meeting are outlined in the table below:

Shareholders are reminded that the last day of dealings in C4X Discovery's ordinary shares on AIM will be 25 April 2024.

With effect from the cancellation of admission of the Company's ordinary shares to trading on AIM, the Company intends to implement a matched bargain facility and has appointed Asset Match  (www.assetmatch.com) to facilitate trading in the Ordinary Shares. This facility will allow Shareholders and new investors to trade Ordinary Shares by matching buyers and sellers through periodic auctions. Full details will be made available to shareholders on the Company's website at www.c4xdiscovery.com and directly by letter or e-mail (where appropriate).

From the date of cancellation, shareholder will be able to request Company news alerts via email on the C4XD website.

Further details regarding the cancellation and re-registration are set out in the circular sent to shareholders dated 27 March 2024. A copy of the circular is available on the Company's website www.c4xdiscovery.com.

- Ends -

Contacts

Notes to Editors:

About C4X Discovery

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Notes:

(1)        All of the times referred to in this announcement refer to London time, unless otherwise stated.

(2)        The timetable above assumes that the Resolutions set out in the Notice of General Meeting are passed. Events listed in the above timetable following the General Meeting are conditional on the Resolutions being passed at the General Meeting without amendment.

(3)        Each of the times and dates in the above timetable is subject to change. If any of the above times and/or dates change, the revised times and dates will be notified to Shareholders by an announcement through a Regulatory Information Service.